Scorpion’s pre-clinical and clinical scale contract biologics manufacturing facility is currently under construction and is scheduled to open in August 2022 in the heart of San Antonio, Texas.
The facility provides 8,000 total square feet of cGMP-compliant cleanroom biomanufacturing space, a 2,000 square-foot process development lab, and a 2,000 square-foot analytical testing lab, as well as office, meeting, warehouse, and mechanical space. Controlled, classified cleanroom space is segregated into two independent biologic manufacturing areas, located in two separate buildings on the VelocityTX campus.
Scorpion provides cGMP contract manufacturing for cell therapy products including cells and exosome/secretome products as well as therapeutic proteins, vaccines, and vectors produced in both mammalian and microbial systems. Scorpion’s biomanufacturing facilities provide world-class capabilities utilizing single-use, disposable technology for cost-effective production. Single-use systems reduce the risk of contamination and/or cross-contamination, allow for quick changeover between batches, and reduce or eliminate the need for cleaning validation studies.
Scorpion utilizes American-manufactured equipment and consumables, such as the Pall Allegro™ STR single-use family of stirred tank bioreactors that deliver consistent and scalable cell culture and microbial fermentation performance. Current capabilities include 50, 200, 500, 1000 and 2000L mammalian cell culture bioreactors and 100L microbial fermentation reactor. Cell harvest capabilities include bioprocess-scale centrifugation, continuous flow centrifugation, kSep 400 as well as microfiltration. Downstream process capabilities include ultrafiltration/diafiltration, column chromatography, sterile filtration, and fill-finish.